KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetShort-Term Debt repayments
Ratios

BeOne Medicines (ONC) Accumulated Depreciation & Amortization (2016 - 2025)

BeOne Medicines (ONC) has disclosed Accumulated Depreciation & Amortization for 11 consecutive years, with $141.7 million as the latest value for Q4 2025.

  • On a quarterly basis, Accumulated Depreciation & Amortization fell 17.51% to $141.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $141.7 million, a 17.51% decrease, with the full-year FY2025 number at $141.7 million, down 17.51% from a year prior.
  • Accumulated Depreciation & Amortization was $141.7 million for Q4 2025 at BeOne Medicines, up from $105.7 million in the prior quarter.
  • In the past five years, Accumulated Depreciation & Amortization ranged from a high of $171.8 million in Q4 2024 to a low of $9.6 million in Q1 2021.
  • A 5-year average of $60.3 million and a median of $47.4 million in 2021 define the central range for Accumulated Depreciation & Amortization.
  • Peak YoY movement for Accumulated Depreciation & Amortization: soared 95.91% in 2024, then dropped 17.51% in 2025.
  • BeOne Medicines' Accumulated Depreciation & Amortization stood at $46.5 million in 2021, then soared by 42.67% to $66.3 million in 2022, then soared by 32.28% to $87.7 million in 2023, then skyrocketed by 95.91% to $171.8 million in 2024, then decreased by 17.51% to $141.7 million in 2025.
  • Per Business Quant, the three most recent readings for ONC's Accumulated Depreciation & Amortization are $141.7 million (Q4 2025), $105.7 million (Q3 2025), and $68.4 million (Q2 2025).